Investors & media

Pure Biologics is a Polish biopharmaceutical company operating in the area of modern biological drugs. On the market since 2010, it was first in Poland to focus on developing new and innovative therapeutic molecules, not simply generic or biosimilar, based on antibodies and aptamers to be used in immuno-oncology and rare diseases applications.

In 2018, Pure Biologics entered the NewConnect market of the Warsaw Stock Exchange, and in 2020 announced moving to the main market.

Our team combines the recruitment of talent from renowned research groups, know-how acquired from years of activity, and an effective operating model, to drive the evolution of our own internal research projects, belonging to the most promising sectors of pharmaceutics.

Sources of funding for our therapeutic portfolio include grants from the European Union, complemented with revenue from contracted research delivered for pharmaceutical and biotechnology companies, as well as the capital invested by our company shareholders. The long-term strategy includes the partial reinvestment of profits from commercialization of our portfolio into our R&D activities and further development of the research program.

Shareholders

30,16%
498817 shares
Filip Jeleń
(Chairman of the Board)
9,68%
160104 shares
Maciej Mazurek
8,68%
146576 shares
Piotr Jakimowicz
7,69%
127220 shares
Augebitz FIZ
5,69%
94170 shares
Jacek Otlewski
4,90%
81000 shares
Andrzej Trznadel
(Chairman of the SB)
33,02%
546113 shares
Other shareholders
30,16%
498817 votes
Filip Jeleń
(Chairman of the Board)
9,68%
160104 votes
Maciej Mazurek
8,68%
146576 votes
Piotr Jakimowicz
7,69%
127220 votes
Augebitz FIZ
5,69%
94170 votes
Jacek Otlewski
4,90%
81000 votes
Andrzej Trznadel
(Chairman of the SB)
33,02%
546113 votes
Other shareholders
Share and votes table
Shareholder % shares % votes
Filip Jeleń 30,16% 30,16%
Maciej Mazurek 9,68% 9,68%
Piotr Jakimowicz 8,68% 8,68%
Augebitz FIZ 7,69% 7,69%
Jacek Otlewski 5,69% 5,69%
Andrzej Trznadel 4,90% 4,90%
Other shareholders 33,02% 33,02%

Calendar of events and reports

15 I
2020
Beginning of closed period before the announcement of quarterly financial report
14 II
2020
Q4 2019 periodic financial report
31 III
2020
Beginning of closed period before the announcement of annual financial report
15 IV
2020
Beginning of closed period before the announcement of quarterly financial report
30 IV
2020
2019 annual financial report
15 V
2020
Q1 2020 periodic financial report
15 VII
2020
Beginning of closed period before the announcement of quarterly financial report
14 VIII
2020
Q2 2020 periodic financial report
13 X
2020
Beginning of closed period before the announcement of quarterly financial report
12 XI
2020
Q3 2020 periodic financial report
Today

Download

Memoranda and prospectuses (PL)

These documents are prepared in connection with the application for the introduction of financial instruments to trading conducted by the Warsaw Stock Exchange S.A.

Contact for investors

Martyna Koj

Head of Management Office, Investor Relations Representative
 

Address for submitting notifications

According to Art. 19 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR)

Autohorised adviser

PROFESCAPITAL Sp. z o.o.
Ofiar Oświęcimskich 15, 50-069 Wrocław
tel: +48 71 782 11 60
www.profescapital.pl

Issuer’s market maker

Trigon Dom Maklerski S.A.
Mogilska 65, 31-545 Kraków
tel. +48 22 330 11 39
www.trigon.pl

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.